RASSF7

Across TCGA pan-cancer cohorts, RASSF7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RASSF7 data layer compared with 29 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RASSF7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RASSF7 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where RASSF7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.459	0.767	.012	15	view →
CCRCC	DFS	Median	III,IV	0.587	0.845	.035	8	view →
LUAD	DFS	Quartile	III,IV	0.333	0.835	.012	5	view →
HNSC	DFS	Quartile	III,IV	0.820	1.000	.037	4	view →
LSCC	DFS	Tertile	III,IV	0.984	0.483	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RASSF7–PDAC (OS)

Open the PDAC breakdown →